Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice

The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide (enzalutamide combination) and enzalutamide monotherapy significantly improved metastasis-free survival compared with leuprolide alone. Furthermore, overall survival was significantly longer with enzalutamide combination compared with leuprolide alone. No new safety signals were observed, and health-related quality of life was maintained with enzalutamide combination and monotherapy (as determined by patient-reported outcomes). In this episode, the speakers discuss some of the results from EMBARK in more detail and provide their expert opinion on what the findings mean for clinical practice in the real world. They also answer some of the frequently asked questions that they receive about the study from people around the world, including discussion of whether the results apply regardless of primary therapy, if intermittent therapy is a possibility, and how the findings from EMBARK should be applied with respect to the availability of different imaging technologies.